"Frontiers of AI" - SXSW London 2025 - Conference - Day One

Demis Hassabis, CEO of drug discovery startup Isomorphic Labs, which has raised Europe’s largest biotech VC round this year

Jack Taylor/Getty Images

Biotech

European VC biotech dealmaking rebounds to record highs

AI adoption, exit momentum and regulatory support have improved investor appetite.
"Frontiers of AI" - SXSW London 2025 - Conference - Day One

Demis Hassabis, CEO of drug discovery startup Isomorphic Labs’ which has raised Europe’s largest biotech VC round this year

Jack Taylor/Getty Images

Biotech VC investing in Europe has rallied this year, with deal value already reaching record levels.

According to PitchBook data, €1.3 billion (about $1.5 billion) has been invested in the sector, an increase of 62.5% over last year’s total and exceeding the previous peak in 2021.

The deal count has slowed somewhat this year, but is still expected to remain within a similar range as 2024’s figure, which was at its highest in a decade.

VC investment in European biotech surged during the pandemic years, but contracted with the broader market correction in 2022. The downturn reset valuations and deal sizes, setting the stage for a rebound this year.

Several outsized deals have closed in 2025. Drug discovery startup Isomorphic Labs’ $600 million raise in March is currently the year’s largest round, underscoring investor appetite for biotech companies that intersect with AI.

The rapid pace of AI development is encouraging more VCs to explore opportunities in biotech. Fields such as drug discovery are especially attractive because AI can speed up years-long processes, cut costs and shorten the timeframe for bringing products to market.

Other notable deals include protein engineering startup GlycoEra‘s $130 million Series B and cancer-focused CellCentric‘s $120 million Series C.

Early-stage rounds now account for the largest share of both deal value and count, reflecting investor confidence in the growing pipeline of European life science startups and university spinouts.

Positive signals in Europe’s biotech exit market may also be boosting investor interest in the sector. Although still below 2021’s peak, 2025 has seen an uptick in acquisitions, with eight closing this year compared to six in 2024.

AstraZeneca‘s $1 billion takeover of lung cancer drug maker EsoBiotec contributed most to exit value, but even without the deal, it is expected to land above last year’s.

Regulatory momentum is adding to the optimism. The EU’s upcoming Biotech Act, which is expected to take effect next year, aims to harmonize rules, accelerate approvals and expand access to capital.

Learn about our editorial standards.